FCP
EW icon

Fidelis Capital Partners’s Edwards Lifesciences EW Stock Holding History

Fidelis Capital Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$388K Buy
4,284
+37
+0.9% +$3.1K 0.02% 387
2026
Q1 		$340K Buy
4,247
+102
+2% +$8.41K 0.02% 379
2025
Q4 		$353K Buy
4,145
+63
+2% +$5.17K 0.03% 371
2025
Q3 		$317K Buy
4,082
+12
+0.3% +$938 0.02% 378
2025
Q2 		$320K Buy
4,070
+469
+13% +$35K 0.03% 335
2025
Q1 		$274K Sell
3,601
-362
-9% -$25.9K 0.03% 336
2024
Q4 		$283K Sell
3,963
-580
-13% -$40.6K 0.03% 346
2024
Q3 		$321K Sell
4,543
-1,028
-18% -$74.7K 0.04% 306
2024
Q2 		$340K Buy
5,571
+507
+10% +$44.9K 0.05% 262
2024
Q1 		$484K Buy
5,064
+690
+16% +$58K 0.07% 214
2023
Q4 		$334K Buy
4,374
+586
+15% +$40.8K 0.07% 230
2023
Q3 		$262K Sell
3,788
-677
-15% -$54.4K 0.09% 217
2023
Q2 		$421K Buy
4,465
+233
+6% +$20.3K 0.15% 151
2023
Q1 		$376K Buy
+4,232
New +$333K 0.16% 147

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Fidelis Capital Partners's EW Position: Q2 2026 in Review

Fidelis Capital Partners increased its Edwards Lifesciences (EW) stake by 0.87% in Q2 2026, buying an estimated $3.1K and bringing the position to 4,284 shares worth $388K. The position accounts for 0.02% of the portfolio, ranked #387.

Fidelis Capital Partners first reported a position in EW in Q1 2023 and has held it in 14 quarters since. The position peaked at $484K in Q1 2024. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Fidelis Capital Partners held 4,284 shares of Edwards Lifesciences worth $388K as of Q2 2026.
  • Fidelis Capital Partners bought 37 Edwards Lifesciences shares in Q2 2026, an estimated $3.1K.
  • Edwards Lifesciences made up 0.02% of Fidelis Capital Partners's portfolio in Q2 2026, its #387 holding.
  • Fidelis Capital Partners first reported a position in Edwards Lifesciences in Q1 2023 and has held it in 14 quarters since.
  • Fidelis Capital Partners's Edwards Lifesciences position peaked at $484K in Q1 2024.
  • 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.